Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1999 3
2002 4
2003 4
2004 4
2005 6
2006 6
2007 5
2008 11
2009 20
2010 19
2011 39
2012 42
2013 65
2014 85
2015 104
2016 116
2017 122
2018 124
2019 141
2020 135
2021 136
2022 118
2023 38
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24434296

1,156 results

Results by year

Filters applied: . Clear all
Page 1
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Carlsen EA, et al. Endocr Relat Cancer. 2019 Feb 1;26(2):227-239. doi: 10.1530/ERC-18-0424. Endocr Relat Cancer. 2019. PMID: 30540557 Free article.
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215
Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors.
Abou Jokh Casas E, Pubul Núñez V, Anido-Herranz U, Del Carmen Mallón Araujo M, Del Carmen Pombo Pasín M, Garrido Pumar M, Cabezas Agrícola JM, Cameselle-Teijeiro JM, Hilal A, Ruibal Morell Á. Abou Jokh Casas E, et al. World J Gastroenterol. 2020 Apr 7;26(13):1513-1524. doi: 10.3748/wjg.v26.i13.1513. World J Gastroenterol. 2020. PMID: 32308351 Free PMC article.
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM, de Herder WW, Krenning EP, Kwekkeboom DJ. Bergsma H, et al. J Nucl Med. 2018 Mar;59(3):452-458. doi: 10.2967/jnumed.117.189712. Epub 2017 Aug 3. J Nucl Med. 2018. PMID: 28775205 Free article.
1,156 results